

# **Présentation de cas et discussion**

**« Cancer du sein »**

**« Cancer du poumon »**


Docteur Jean Lépine

Journée scientifique en oncologie

CSSS de Rimouski-Neigette

Le 18 septembre 2009

# Risk of Recurrence in Early Breast Cancer: St. Gallen 2007 — Revised Definitions of Risk



pT = pathologic tumor size; G = grade (histologic and/or nuclear); PVI = peritumoral vascular invasion

Adapted with permission from Piccart-Gebhart MJ. Primary presentation. SABCS, 2005, San Antonio, Tex.  
Goldhirsch A et al. Ann Oncol. 2007; 18: 1133-1144

# Adjuvant! Online

Decision making tools for health care professionals

## Adjuvant! for Breast Cancer (Version 8.0)

### Patient Information

Age:

Comorbidity:

ER Status:

Tumor Grade:

Tumor Size:

Positive Nodes:

Calculate For:

10 Year Risk:

### Adjuvant Therapy Effectiveness

Horm:

Chemo:

Hormonal Therapy:

Chemotherapy:

Combined Therapy:

#### No additional therapy:



**68.4 alive and without cancer in 10 years.**

**24.0 relapse.**

**7.6 die of other causes.**

#### With hormonal therapy: Benefit = 8.5 without relapse.



#### With chemotherapy: Benefit = 2.4 without relapse.



#### With combined therapy: Benefit = 10.1 without relapse.




Print Results PDF

Access Help and Clinical Evidence

Images for Consultations

# Adjuvant Endocrine Agents: EBCTCG Tamoxifen Overview

- Useful regardless of menopausal status
- In postmenopausal women:
  - Reduces recurrence by 37 – 54%
  - Reduces death by 11 – 33%
- Long-term side effects characterized
- Carry-over effect documented
- Utility in sequence with AIs in post-menopausal women



*Early Breast Cancer Trialists, Lancet 2005.*


# Recent Adjuvant Endocrine Therapy Trials

Type of Trial	Trial Design	Trial Name
Initial Adjuvant	Tamoxifen	ATAC (N = 9366)
	AI	BIG 1-98 (N = 6193)
Initial and Sequencing	Tamoxifen	BIG 1-98 (N = 6193)
	AI	
	Tamoxifen	
	AI	
Sequencing	Tamoxifen	ABCSG 8 (N = 3224)
	AI	
Switching	2-3 Years Prior Tamoxifen	ARNO 95 (N = 979)
	Tamoxifen	ITA (N = 488)
Extended Adjuvant	AI	MA.17 (N = 5157)
	5 Years Tamoxifen	ABCSG-6A (N = 856)

ABCSG = Austrian Breast and Colorectal Cancer Study Group; ARNO = Arimidex-Nolvadex; ATAC = Arimidex, Tamoxifen, Alone or in Combination; BIG = Breast International Group; IES = Intergroup Exemestane Study; ITA = Intergruppo Tamoxifen/Anastrozolo.

# The Natural History of HR+ Breast Cancer is Very Long


- ER+ tumors demonstrate a relatively constant hazard of recurrence over time
- After TAM x 5 years, over half of all recurrences occur in years 6-15 (EBCTCG, Lancet 2005)
- MA-17: risk of recurrence was approx 2-3% each year on placebo arm (Ingle, SABCs 2005)
- ATAC: 2% annual risk of recurrence after completion of 5 years of AI (Forbes, 2008)



# AI Arthralgia Syndrome

- Common complaint; typically symmetric discomfort in hands, feet, pelvis/hip
- Pathognomonic criteria:
  - “I aged overnight.” “I feel like an old lady.”
  - Squeezing hands/joints gesture






**Number at risk**

	1	2	3	4	5	6	7	8	9
Tamoxifen	2976	2824	2699	2572	2419	2208	2000	1645	659
Anastrozole	2984	2859	2745	2640	2496	2306	2077	1713	702




# BMD Loss With Cancer Therapies




1. Riggs LA. *Osteoporosis*. Blackwell Healthcare Communications Ltd, 1997:22-56. 2. Eastell R et al. *J Bone Mineral Res*. 2002;17(suppl 1):S165. Abstract 1170. 3. Lee WY et al. *J Clin Endocrinol Metab*. 2002;87:329-335. 4. Mascherit JF et al. *J Clin Oncol*. 1999;16:1219-1222. 5. Grant M. *San Antonio Breast Cancer Symposium*, 2002. 6. Shapiro CL et al. *J Clin Oncol*. 2001;19:3306-3311.

# Recommandations pour le traitement et la prévention de la perte osseuse secondaire au traitement par les IA



^Une baisse de la DMO  $\geq 5$  % justifie d'instaurer un traitement par AZ (4 mg q 6 mois).  
Adapté de : Hadji P, *et al.* Communication présentée au SABCS 2007; affiche 504.


# ASCO Guidelines for Treating CTIBL in Breast Cancer



\*Not recommended after tamoxifen or with AIs.  
CTIBL = cancer treatment-induced bone loss.  
Hilner et al. J Clin Oncol. 2003;21:4042.

## HEAL THYSELF

Factors breast-cancer survivors cite in preventing a recurrence:



Source: D. E. Stewart et al., "Attributions of Cause and Recurrence in Long-Term Breast Cancer Survivors," 2001.

Chart by Charles M. Blow

NY Times Magazine 6/29/08

# Modèle d'une entrevue ("SPIKES")

1. Préparer l'entrevue
2. Vérifier la perception
3. Définir la relation
4. Échanger l'information
5. Explorer les émotions
6. Terminer la rencontre

# Explorer les émotions ("EVE")

- Explorer
  - identifier l'émotion
- Valider
  - identifier la source
  - normaliser l'émotion
- Signifier son empathie
  - confirmer la relation cause/effet